Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Circulation Research. 1989;64:227-234

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rosengart, T. K.
Right arrow Articles by Clark, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rosengart, T. K.
Right arrow Articles by Clark, R. E.

Circulation Research, Vol 64, 227-234, Copyright © 1989 by American Heart Association

ARTICLES

Pharmacokinetics and distribution of heparin-binding growth factor I (endothelial cell growth factor) in the rat

TK Rosengart, JP Kuperschmid, T Maciag and RE Clark
Surgery Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892.

Heparin-binding growth factor I (HBGF I), previously designated as endothelial cell growth factor, is a potent mitogen for endothelial cells in vitro, which may prove useful for promoting endothelial regeneration in vivo. Analysis of the pharmacokinetics and organ distribution of HBGF I is necessary before use of HBGF I as a pharmacological agent. Consequently, pharmacological studies were carried out with [125I]HBGF I in the rat. Intravenous injections of HBGF I were given with or without heparin (2.5 units/ng HBGF I). Blood concentrations of HBGF I decreased by one half 17 seconds after HBGF I bolus. This time was prolonged to 60 seconds when HBGF I was injected with heparin. The elimination half-life of HBGF I was 14 minutes in the presence of heparin. The highest concentrations of HBGF I following intravenous bolus were found in kidney, liver, and spleen, and the lowest in fat and brain. Heparin increased HBGF I concentrations in blood and all organs measured except kidney, which was significantly decreased (p less than 0.01). Intact HBGF I was recoverable from blood 5 minutes following intravenous administration. HBGF I underwent near- complete proteolytic digestion after more prolonged ex vivo incubation with rat plasma, but HBGF I was protected from proteolysis when incubations were conducted in the presence of heparin. Thus, it is feasible that HBGF I can be administered as a pharmacological agent in the presence of heparin. Further studies assessing acceleration of in vivo endothelial growth using HBGF I with heparin appear warranted.


This article has been cited by other articles:


Home page
 CirculationHome page
K. N. Le, C.-W. Hwang, A. R. Tzafriri, M. A. Lovich, A. Hayward, and E. R. Edelman
Vascular Regeneration by Local Growth Factor Release Is Self-Limited by Microvascular Clearance
Circulation, June 9, 2009; 119(22): 2928 - 2935.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
V. Lindner and T. Maciag
The Putative Convergent and Divergent Natures of Angiogenesis and Arteriogenesis
Circ. Res., October 26, 2001; 89(9): 747 - 749.
[Full Text] [PDF]

Home page
 ScienceHome page
P Cuevas, F Carceller, S Ortega, M Zazo, I Nieto, and G Gimenez-Gallego
Hypotensive activity of fibroblast growth factor
Science, November 22, 1991; 254(5035): 1208 - 1210.
[Abstract] [PDF]


Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 1989 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.